We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

16 hedge funds and large institutions have $625K invested in Kiora Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

33% more funds holding

Funds holding: 12 → 16 (+4)

0% less ownership

Funds ownership: 0% → 0% (-0%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

68% less capital invested

Capital invested by funds: $1.93M → $625K (-$1.31M)

Holders
16
Holders Change
+4
Holders Change %
+33.33%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$43.2K
2
US Bancorp
US Bancorp
Minnesota
+$34.6K
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$21.6K
4
Citadel Advisors
Citadel Advisors
Florida
+$17.3K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$13K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$156K
2
VF
Virtu Financial
New York
-$77K
3
AC
Armistice Capital
New York
-$73.5K
4
Macquarie Group
Macquarie Group
Australia
-$27K
5
TSS
Two Sigma Securities
New York
-$17.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$453K -$73.5K -17 -7%
Vanguard Group
2
Vanguard Group
Pennsylvania
$28K -$156K -36 -72%
IA
3
IFP Advisors
Florida
$25K – – –
Citadel Advisors
4
Citadel Advisors
Florida
$22K +$17.3K +4 +67%
Barclays
5
Barclays
United Kingdom
$20K +$43.2K +10 New
US Bancorp
6
US Bancorp
Minnesota
$15K +$34.6K +8 New
Bank of New York Mellon
7
Bank of New York Mellon
New York
$11K +$21.6K +5 New
CS
8
Credit Suisse
Switzerland
$10K +$4.32K +1 +25%
WS
9
Wedbush Securities
California
$8K – – –
Northern Trust
10
Northern Trust
Illinois
$6K – – –
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$6K +$13K +3 New
TSS
12
Two Sigma Securities
New York
$5K -$17.3K -4 -67%
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$5K +$8.64K +2 New
LTFS
14
Ladenburg Thalmann Financial Services
Florida
$4K +$8.64K +2 New
Morgan Stanley
15
Morgan Stanley
New York
$3K +$4.32K +1 New
VIA
16
Vantage Investment Advisors
Pennsylvania
$2K – – –
UBS Group
17
UBS Group
Switzerland
$1K -$4.32K -1 Closed
HFP
18
Holistic Financial Partners
Indiana
$1K – – –
VF
19
Virtu Financial
New York
– -$77K -13 Closed
Macquarie Group
20
Macquarie Group
Australia
– -$27K -5 Closed
WTB
21
Washington Trust Bank
Washington
– -$2K – –

KPRX Hedge Fund Activity: Q1 2018 in Review

16 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2018, worth a combined $625K — down 68% from $1.93M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new KPRX positions and 3 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Barclays, opening a new position worth an estimated $43.2K. The largest seller was Vanguard Group, cutting an estimated $156K.

  • 16 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2018, up from 12 in Q4 2017.
  • Funds reported $625K of Kiora Pharmaceuticals stock for Q1 2018, down 68% quarter-over-quarter.
  • 7 funds opened new Kiora Pharmaceuticals positions in Q1 2018 and 3 closed out, a net change of +4 holders.
  • The largest Kiora Pharmaceuticals buyer in Q1 2018 was Barclays, an estimated $43.2K added.
  • The largest Kiora Pharmaceuticals seller in Q1 2018 was Vanguard Group, an estimated $156K sold.

Based on aggregated 13F filings for Q1 2018.